Canada authorizes Moderna flu and flu–COVID vaccines for adults 50 and older

Canadian community and institutional pharmacy teams have two new vaccine authorizations to track. Health Canada authorized Moderna’s mFLUSIVA influenza vaccine and mCOFLU influenza–COVID-19 combination vaccine for adults aged 50 and older on November 4, 2026. The company announced the decisions the following day. The dates appear in the mFLUSIVA and mCOFLU product monographs.

Key takeaways

• mFLUSIVA targets influenza; mCOFLU combines influenza and COVID-19 components. They are different products, not interchangeable names.
• An authorization does not establish that a pharmacy can order the product now or bill a public program for it.
• The supporting studies use different endpoints. A result for the influenza-only vaccine should not be presented as a result for the combination vaccine.

What the evidence does—and does not—show

The mFLUSIVA monograph describes a large randomized trial comparing the vaccine with a standard-dose influenza vaccine. Its reported relative efficacy against laboratory-confirmed influenza was 26.6%, with a 95% confidence interval of 16.7% to 35.4%. That is a relative comparison with the trial comparator, not a 26.6-percentage-point reduction in everyone’s risk, and not a comparison with every influenza vaccine on the Canadian market. Read the trial and indication sections.

For mCOFLU, the pivotal comparison assessed immune responses against the influenza and COVID-19 components in two age groups. Meeting an immune-response endpoint is not the same as directly measuring a reduction in hospital admissions or deaths. Readers should not transfer a clinical efficacy number from mFLUSIVA to mCOFLU. The combination-product monograph sets out its own evidence and limitations.

Authorization is only one part of a pharmacy launch

The monographs reviewed for this report identify the authorized formulations as 2024–2025 influenza formulations; the combination document also identifies an Omicron JN.1 COVID-19 component. Those labels are an important reason not to assume these authorizations establish the products or strains that will be supplied for a later vaccination campaign. Moderna’s announcement should be read alongside, not instead of, the product documents.

For an immunizing pharmacy, a launch-readiness checklist therefore needs separate answers to several questions: Which exact product and formulation is being supplied? Is it included in the applicable program? Who can receive it under local policy? What ordering, storage and documentation arrangements apply? A positive answer to one question cannot substitute for the others.

Practice guidance for pharmacists

• Keep the two product names distinct in staff education, booking information and patient discussions.
• Check the current monograph and provincial or territorial program notice before adding either product to an appointment menu.
• Confirm the supplied formulation and local availability; do not promise access on the basis of an authorization headline.
• Explain the difference between clinical protection endpoints and immune-response comparisons when discussing the evidence.
• Review product-specific administration and storage instructions before receipt, and update documentation workflows before first use.

The next practical milestones are confirmed supply and program decisions. Until those are established, the appropriate message is that Canada has authorized new options for a defined age group—not that every pharmacy has a new funded vaccination service available today.